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Abstract 
Glucagon-like peptide-1 (GLP-1) and serotonin play critical roles in energy balance regulation. 
Both systems are exploited clinically as anti-obesity strategies. Surprisingly whether they 
interact in order to regulate energy balance is poorly understood. Here we investigated 
mechanisms by which GLP-1 and serotonin interact at the level of the CNS. Serotonin depletion 
impaired the ability of exendin-4, a clinically utilized GLP-1 analogue, to reduce body weight in 
rats, suggesting serotonin is a critical mediator of the energy balance impact of GLP-1R 
activation. Serotonin turnover and expression of 5HT2A and 5HT2C serotonin receptors in the 
hypothalamus were altered by GLP-1R activation. We demonstrate that 5HT2A, but surprisingly 
not 5HT2C, receptor is critical for weight-loss, anorexia and fat mass reduction induced by 
central GLP-1R activation. Importantly, central 5HT2A receptors are also required for peripherally 
injected liraglutide to reduce feeding and weight. Dorsal raphe (DR) harbors cell bodies of 
serotonin producing neurons that supply serotonin to the hypothalamic nuclei. We show that 
GLP-1R stimulation in DR is sufficient to induce hypophagia and increase electrical activity of the 
DR serotonin neurons. Finally our results disassociate brain metabolic and emotionality 
pathways impacted by GLP-1R activation. This study identifies serotonin as new critical neural 
substrate for GLP-1 impact on energy homeostasis, and expands the current map of brain areas 
impacted by GLP-1R activation. 
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Introduction 
Glucagon-like peptide-1 (GLP-1), a peptide produced in the brain and in the intestine, is a critical 
regulator of energy balance; its glucoregulatory and anti-obesity properties are currently 
successfully utilized in the clinic (1-3). While the ability of GLP-1 and its stable analogues, 
exendin-4 (EX4) for example, to reduce food intake is well established, the brain mechanisms 
governing GLP-1 receptor (GLP-1R)-induced anorexia are still poorly understood. 
Serotonin has long been explored for its potential as an anti-obesity treatment, with a mixed 
success history, primarily due to troublesome side effects of drugs broadly affecting the 
serotonin system (4). Lorcaserin (Belviq ©) is currently the only serotonin receptor activating 
anti-obesity pharmaceutical which is still approved for clinical use; it acts as a 5HT2C agonist 
while to a lesser extent also activating 5HT2A receptors. In line with its anorexic and weight-
reducing role, central injections of serotonin or its precursor reduce food intake (5, 6). 
Conversely, brain serotonin depletion leads to hyperphagia and obesity (7, 8), though this effect 
is not always replicated (9, 10). Serotonin signals through at least 18 receptors; thus far the 
5HT2C receptor received most attention for its anorexic and weight loss impact (4, 11, 12). 
Surprisingly little is known about the interaction of the central GLP-1 and serotonin systems. 
However existing data suggest that an interaction is possible: 1. GLP-1 and EX4 have been 
shown to dose dependently release serotonin from rat hypothalamic synaptosomes (13); 2. 
GLP-1 receptors have been identified in the dorsal raphe nucleus (DR), a nucleus harboring cell 
bodies of serotonergic neurons supplying serotonin to many forebrain sites including the 
Page 3 of 38
3 
Diabetes
hypothalamus (14-16); 3. Molecular mechanism for the induction of serotonin by GLP-1R 
activation is suggested by a recent study showing that, at the level of the colon, EX4 attenuates 
hyperalgesia by increasing colonic serotonin production (17). At the level of the colon the GLP-1-
serotonin interaction may be reciprocal since serotonin or serotonin 5HT1B receptor agonists 
also increase GLP-1 secretion from the enteroendocrine cells (18, 19). 
Here we employed several methodological approaches to determine whether the two clinically 
relevant anti-obesity systems interact and to identify the neuroanatomical mechanism of this 
interaction. Behavioral, neuropharmacological, electrophysiological and neuroanatomical 
results obtained here support a direct impact of central GLP-1 activation to increase central 
serotonin neurotransmission, a relationship discovered to be critical for GLP-1-induced weight-
loss or weight-loss maintenance and hypophagia. 
Research Design and Methods 
Animals 
Adult male Sprague-Dawley rats, weighing 200-250g (Charles River, Germany) were housed in 
individual plastic cages under 12/12 hours dark/light cycle, at 20
°
C and 50% humidity. Adult 
female and male mGLU-124 Venus yellow fluorescent protein transgenic mice (YFP-PPG mice; 
University of Cambridge, United Kingdom (20)) were housed in plastic cages. Water and 
standard chow were available ad libitum. All studies were carried out with ethical permissions 
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from the Animal Welfare Committee of the Göteborg University (permission 195-13), in 
accordance with legal requirements of the European Community (Decree 86/609/EEC). 
Drugs 
GLP-1 (7-36), Exendin-4 (EX4; GLP-1R agonist), Exendin 9-39 (Ex9-39; GLP-1R antagonist), para-
chlorophenylalanine (PCPA), R-96544 (selective 5HT2A antagonist (21)), SB242084 (5HT2C 
antagonist (22)), and angiotensin II were purchased from Tocris (Bristol, UK). All substances, 
except for SB242084, liraglutide, and PCPA, were dissolved in artificial cerebrospinal fluid 
(aCSF), vehicle for central injections. Liraglutide (Bachem) was dissolved in 0.9% saline. PCPA 
was dissolved in 0.9% saline by gentle warming and sonication to a concentration of 100 mg/ml 
(23, 24). SB242084 was dissolved in 16% DMSO. 5HT2C receptor antagonist SB242084 displays 
158- and 100-fold selectivity over 5HT2A and 5HT2B receptors respectively and it also displays 
selectivity over a range of other 5-HT, dopamine and adrenergic receptors. R-96544 is a potent, 
selective 5HT2A receptor antagonist; R-96544 shows 100-fold higher affinity for the human 
5HT2A receptors than 5HT1A, 5HT1B, 5HT1D, 5HT5A, 5HT6, 5HT7 receptors and 5-HT transporter, 
although R-96544 has relatively high affinity for 5HT2C receptors (fourfold less compared to 5-
HT2A) (21). 
Brain cannulation 
Rats were implanted with a guide cannula (26 gauge cannula; Plastics One, Roanoke, VA) as 
described previously (25) to allow drug injections into lateral ventricle (LV) or DR. The following 
injection coordinates were used: ±1.6mm/-0.9mm/-4.0mm for LV and 0.0mm/-7.7mm/-6.8mm 
for DR (given from midline/bregma/skull). The LV placement was verified with the angiotensin II 
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drinking test (26). The microinjection site for the DR guide cannula was verified post mortem by 
microinjection of India ink at the same microinjection volume (0.3μl) used throughout the study. 
RNA isolation and mRNA expression 
Hypothalamic gene expression levels were measured after chronic (daily, for 10 days) LV 
injections of EX4 (0.2µg) or vehicle (aCSF). A third group of rats was included to determine 
whether chronic GLP-1R activation interacts with weight loss-induced changes in serotonin 
receptors. These rats were pair-fed daily to the amount of chow eaten by the EX4-treated rats. 
The following serotonin receptor genes were examined: Htr1a, Htr2a, Htr2c, Htr3a. These genes 
were chosen based on their previously shown connection to GLP-1R activation or their well-
established role in feeding regulation (see discussion section for details). Brains were rapidly 
removed 24h after the last EX4 injection and the hypothalamus was dissected. Gene expression 
was determined using TaqMan RT-PCR and primer/probe sets as described previously (26-28) 
(for reference numbers see table 1 SI). Gene expression values were calculated based on the
Ct method (29), with vehicle-injected group set as the calibrator. PPIA (peptidylprolyl 
isomerase A) was used as a reference gene. 
Immunohistochemistry 
Mice were anaesthetized and perfused transcardially with heparinized saline followed by 
buffered fixative solution. The GLP-1 fibers and TPH positive neurons were visualized with a 
confocal microscope (LSM 700; Carl Zeiss AG). Antibodies, manufacturers, and dilutions are 
listed in Supplementary Table 2. 
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Whole-cell electrophysiology 
Coronal slices of rat brainstem, 200μm thick, containing DR were cut in ice-cold extracellular 
solution using a vibratome and maintained in incubation chamber at room temperature. Whole-
cell recordings where obtained from visually-identified neurons using glass pipettes containing 
(in mM): 130 K-gluconate, 2 NaCl, 1 MgCl2, 10 Hepes, 0.1 EGTA, 10 Na phosphocreatine, 4 
MgATP, 0.5 Na2GTP, biocytin 0.1%, pH 7.3. Continuous recordings of the membrane potential 
(Vm) were used to monitor the effect of EX4. The input resistance (Rinput) was calculated from 
the response to hyperpolarizing current pulses injected through the recording pipette. EX4 or 
Ex9-39 were added to the superfusion buffer. Electrophysiological data were analyzed with 
pClamp10 (Molecular Devices). Pooled data were presented as mean±SEM; a repeated 
measures ANOVA was used to determine significance since vehicle baseline and EX4 or Ex9-39 
and EX4 effects were measured in the same neuron. DR slices were fixed with PFA 4% after 
recording. Fluorescence images of labeled sections were acquired with a confocal microscope 
(TCS SP5, Leica Microsystems) and reconstructed in 3 dimensions to assess TPH expression in 
biocytin-containing cells. 
Serotonin turnover 
Brains were dissected 24h after the last EX4 injection (injections were given daily for 8 days). 
Brains were rapidly removed and the hypothalamus was dissected using a brain matrix. Tissue 
concentrations of serotonin and its metabolite (5-HIAA) were determined via high performance 
liquid chromatography (30). 
Forced swim test (FST) 
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The FST was originally developed by Porsolt and colleagues (31) to screen for the anti-
depressive effect of pharmacotherapeutics. Here we used the modified version of the FST 
shown to provide a greater reliability for detection of depressant or antidepressant-like effects 
for compounds that affect the serotonergic system (32). The test was performed as previously 
described (26). 
Experimental design 
Effect of serotonin depletion on weight-loss impact of GLP-1R activation 
To assess the impact of serotonin depletion on the weight-loss effect of GLP-1R activation, 
serotonin depleted rats were injected with EX4 and their body weight was followed for five 
consecutive days of central EX4 injections.  Serotonin depletion was performed by three 
intraperitoneal injections of PCPA, an irreversible inactivator of TPH, an enzyme required for the 
synthesis of serotonin. Rats received one daily injection of 300mg/kg for 3 days. This treatment 
regimen was previously shown to decrease serotonin content to 5–10% of original levels (24, 
33), in our hands serotonin turnover in the hypothalamus was still reduced by over 40% one 
week after the PCPA treatment (2.53±0.2 vs. 1.57±0.2: serotonin turnover 5-HIAA/5-HT for 
vehicle- and PCPA-treated rats respectively; p<0.01). Control rats received saline injections. 24h 
after the last PCPA injection, daily EX4 (0.2µg) or vehicle (1µl of aCSF) injections commenced. 
Dose of EX4 was chosen based on (25, 34, 35). 
Effect of 5HT2A or 5HT2C receptor blockade on feeding and weight-loss impact of GLP-1R 
activation 
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Rats were divided into the following four groups, matched for body weight: vehicle (1µl 
aCSF)/vehicle (1µl aCSF), vehicle/EX4 (0.2µg), R-96544 (10µg)/EX4, R-96544/vehicle to test the 
impact of 5HT2A blockade. To test the contribution of 5HT2C receptors rats were divided into the 
following four groups, matched for body weight at the start of the experiment: vehicle (1µl of 
16%DMSO in aCSF)/vehicle (1µl aCSF), vehicle/EX4 (0.2µg), SB242084 (10µg)/EX4, SB242084 
/vehicle. The injection of the antagonist was performed 10 minutes before the injection of the 
agonist or the respective vehicle. All injections were performed once a day, during mid light 
cycle, and intra-LV (total of 8 days of injections). Gonadal white adipose tissue (GWAT) pads 
were dissected 24h after the last injection. In an additional group of rats we tested whether 
central blockade of the 5HT2A receptor attenuates the weight loss induced by peripherally (ip) 
injected liraglutide (75 µg/kg). 
Intra-DR GLP-1R activation 
Vehicle (0.3µL/aCSF), EX4 (0.05µg), or GLP-1 (2µg) were injected into the DR of rats that were 
mildly food restricted (50% of their normal overnight chow) to promote reliable consumption of 
chow after the DR-injections. The intake of chow was measured at 1 and 24h; body weight 
change was measured at 24h after intra-DR injection. These doses were chosen to be below LV 
threshold for effect to avoid potential confounding effect of potential drug leakage into the 
cerebral aqueduct located just above the DR. 
Statistics 
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All statistical analysis was performed in Graph Pad Prism software (San Diego, CA). Statistical 
significance was analyzed using ANOVA followed by Holm-Sidak´s multiple comparison test or 
students t-test as appropriate. All data are presented as mean±SEM. 
Results 
Serotonin depletion attenuated EX4-induced weight loss maintenance. 
Serotonin synthesis is initiated by hydroxylation of tryptophan, a rate-limiting reaction 
performed by the enzyme tryptophan hydroxylase (TPH) in the brain. PCPA acts as a selective 
and irreversible inhibitor of TPH. To evaluate whether intact serotonin synthesis is necessary for 
the energy balance impact of GLP-1R activation, serotonin was depleted by a well-established 
treatment regimen of three-day intraperitoneal PCPA injections (24, 33). Consistently with a 
critical downstream role of serotonin in the weight loss effect of GLP-1R stimulation, serotonin 
depletion resulted in an attenuation of EX4-induced weight loss maintenance (Figure 1A). Two-
way repeated measures ANOVA on body weight data indicated significant effect of drug 
treatment (F(3, 15)=18.69; P<0.0001) and treatment day (F(4, 60)=4.655; P<0.005), but no significant 
interaction of treatment and time (F(12, 60)=0.517; P=0.896). Holm-Sidak's multiple comparisons 
test indicated a significant weight loss effect induced by EX4 for all testing days. In contrast EX4 
did not exert any significant effect on body weight in the rat group that has been depleted of 
serotonin by PCPA as compared to vehicle-injected rats. A significant difference in weight loss 
between EX4 vs. PCPA/EX4 rats was however detected 48h after the first EX4 injection (Holm-
Sidak's test: day 1 t=1.7, P=ns; day 2 t=2.7, P<0.05; day 3 t=2.7, P<0.05; day 4 t=3.2, P<0.01; day 
5 t=3.0, P<0.05). A significant difference in weight loss was also detected between PCPA/VEH vs. 
Page 10 of 38
10 
Diabetes
PCPA/EX4 rats on day 1, 2, and 5 (Holm-Sidak's test: day 1 t=3.0, P<0.05; day 2 t=2.7, P<0.05; 
day 3 t=1.8, P=ns; day 4 t=1.4, P=ns; day 5 t=2.5, P<0.05). This indicates that serotonin signaling 
may not be essential for the weight loss effect of EX4 acutely, but is crucial in a sub-chronic 
setting. PCPA/VEH animals did not increase in weight; this lack of effect of PCPA alone for male 
rats is consistent with a previous report (9). 
Chronic central GLP-1R stimulation affected hypothalamic serotonin receptor expression 
The hypothalamus is a major target site for the energy balance effect of serotonin. In order to 
determine whether GLP-1R activation changes hypothalamic serotonin signaling we measured 
changes in hypothalamic serotonin receptors and serotonin turnover after central chronic EX4 
or GLP-1 treatment. Central injection of EX4 or GLP-1 abolished the increase of hypothalamic 5-
HT1A, 5-HT2A, 5-HT2C and 5-HT3A induced by the restricted feeding (F(3, 41)=6.85, p<0.001; F(3, 
399)=6.35, p<0.001; F(3, 41)=5.14, p<0.005; F(3, 41)=6.34, p<0.005, respectively for each receptor, 
Figure 1B). Feeding was restricted to the daily amount voluntarily eaten by EX4-treated rats. 
While food restriction elevated the mRNA of all serotonin receptors tested, this change reached 
significance only for Htr2a and Htr2c mRNA (Figure 1B). Of note the food restriction promoted 
increased expression of these two receptors also when both control and food-restricted groups 
did not receive cannulation or injection (Figure S1). Consistent with the idea that GLP-1R 
activation increases serotonin neurotransmission in order to produce hypophagia we found that 
serotonin turnover was increased in the hypothalami of EX4-treated rats (Figure 1C). 
5HT2C receptor blockade does not attenuate EX4-induced weight loss or anorexia 
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The antagonist used to block 5HT2A receptors (below), R-96544, offers a very high selectivity for 
all but one serotonin receptor – it only offers four-fold selectivity for the 5HT2C receptor. Due to 
the possibility of some contribution of 5HT2C blockade by the R-96544 to the results obtained, 
along with the well-established role of 5HT2C stimulation in weight-regulation, we tested 
whether a selective 5HT2C receptor antagonist was sufficient to attenuate the impact of EX4 on 
body weight, fat deposition and food intake. Selective blockade of 5HT2C with SB242084 did not 
attenuate EX4-induced weight-loss (Figure 2A). Surprisingly blockade of the 5HT2C receptor 
slightly and significantly exacerbated the EX4-induced weight loss. Two-way repeated measures 
ANOVA on body weight data indicated a significant interaction (F(18, 162)=1.998; P<0.05), 
significant effect of drug treatment (F(3, 27)=34.12; P<0.0001) and treatment day (F(6, 162)=3,099; 
P<0.01). While the reduction of food intake by EX4 seemed exacerbated by the SB242084, this 
effect was not significant (Figure 2B). Also for food intake a significant interaction (F18, 
162)=15.38; P<0.0001), effect of drug treatment (F(3, 27)=49.85; P<0.0001) and treatment day (F(6, 
162)=748.7; P<0.0001) were found. The weight of GWAT was clearly reduced by the sub-chronic 
central EX4 treatment but this effect was not altered by coapplication of the 5HT2C antagonist 
(Figure 2C; F(3, 27)=5.329; P<0.01). It is unlikely that the lack of attenuation of the weight loss and 
anorexia induced by EX4 are due to insufficient dose of the drug, since previous reports have 
reported even lower doses of the drug applied into the brain (intracerebroventricular) to be 
effective in changing food intake in mice or rats (36, 37). Trends in reduced FST immobility after 
EX4 treatment were detected (Figure 2D), although these results did not receive statistical 
significance, irrespective of the antagonist coapplication, due to large variability in the 
antagonist administered group. 
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5HT2A receptor blockade attenuated EX4-induced weight loss and anorexia 
Because 5HT2A and 5HT2C were two hypothalamic receptors we found to be responsive to food 
restriction, and central chronic EX4 treatment, we hypothesized that their pharmacological 
blockade should impair the metabolic impact of EX4. In line with this idea, central blockade of 
5HT2A receptor, with the selective antagonist R-96544, significantly attenuated the weight loss 
induced by EX4 (Figure 3A). Interestingly, the onset of attenuation was delayed to 48h after the 
injections of EX4 suggesting that the 5HT2A receptor becomes essential to the weight-loss effect 
only after two days of treatment, while it seems dispensable for the acutely induced weight loss. 
Two-way repeated measures ANOVA on body weight data indicated a significant interaction 
(F(18, 156)=6.104; P<0.0001), significant effect of drug treatment (F(3, 26)=13.87; P<0.0001) and a 
significant effect of treatment day (F(6, 156)=5,893; P<0.0001). An identical pattern of effect of 
treatment impact was detected for food intake (Figure 3B), with a significant interaction (F(18, 
156)=25.68; P<0.0001), significant effect of drug treatment (F(3, 26) = 985.6; P<0.0001), and a 
significant effect of treatment day (F(6, 156)=29.21; P<0.0001).  In line with the food intake and 
body weight results the GWAT weight was potently reduced by the sub-chronic central EX4 
treatment, an effect completely abolished by the co-treatment with the 5HT2A antagonist 
(Figure 3C). One-way ANOVA indicated a significant effect of the treatment on the GWAT weight 
(F(3, 23)=3.328; P<0.05). Since sub-chronic (but not acute) central EX4 treatment was recently 
shown to reduce depression-like behavior (26) in rat FST and serotonin has a well-established 
role in regulation of emotionality we hypothesized that the anti-depression action of EX4 may 
be mediated by the central 5-HT2A receptors. Data obtained did not support this idea, and 
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clearly indicate that 5-HT2A blockade did not affect the EX4-induced reduction of immobility in 
the FST (Figure 3D). 
Central blockade of 5HT2A receptor also significantly attenuated the weight loss induced by 
peripherally injected liraglutide (Figure 4A). The pattern of results was somewhat different from 
that obtained with EX4, since the intraperitoneally-injected liraglutide was much less potent at 
reducing body weight, and, interestingly, the 5HT2A blockade was effective already at 24h. Two-
way repeated measures ANOVA on body weight data indicated a significant interaction, 
significant effect of drug treatment (F(3,32)=6.282; P<0.005) and a significant effect of treatment 
day (F(4, 128)=184.5; P<0.0001). A similar pattern of effect was detected for food intake (Figure 
4B): significant interaction, significant effect of drug treatment (F(3, 32)=5.82; P<0.005), and 
significant effect of treatment day (F(6, 156)=29.21; P<0.0001) were found.  The amount of weight 
loss differed among the four GLP-1 analogue-treated rat groups (Figure 1A, 2A, 3A, 4A), this is 
likely because each of these groups received different vehicle treatments for the accompanying 
serotonin signaling targeting drug, or different GLP-1 analogues displaying different potency of 
effect, or different route of administration (peripheral vs. icv) resulting in different effect 
strength. Importantly, however, the interaction with serotonin discovered here persisted 
irrespective of the degree of weight loss induced by the GLP-1 analogues. Thus, the interaction 
is not restricted to cases where GLP-1 analogues result in largest weight loss.
Acute intra-DR administration of GLP-1 or EX4 is sufficient to reduce food intake 
Acute injections of EX4 (0.2µg) or GLP-1 (10µg) into the brain ventricles (here intra-LV) reduced 
food intake at 1h (ANOVA; F(2, 30)=9.37, p<0.001) for both EX4 and GLP-1 and at 24h (F(2, 30)=8.34, 
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p<0.005) for EX4 (Figure 5A). This application route likely delivers the GLP-1R agonists to many 
brain sites from which a potential anorexic effect can be elicited. Since both serotonin depletion 
and the 5HT2A receptor blockade suggested an interaction of GLP-1R activation with serotonin, 
we hypothesized that GLP-1 may be exerting a part of its anorexigenic and weight-loss effects 
by acting directly on the DR. Rats microinjected with GLP-1 or EX4 into the DR ate significantly 
less chow both at 1h (ANOVA; F(2, 23)=4.17, p<0.05) and 24h (F(2, 23)=5.01, p<0.05, Figure 5B). The 
weight loss of rats injected with either EX4 or GLP-1 did not, however, reach statistical 
significance (F(2,23)=1.39, p=0.26, Figure 5C). Intra-DR GLP-2 microinjections did not change food 
intake or body weight (Figure S2). 
GLP-1R activation increased the electrical activity of DR 5-HT neurons 
To investigate the effect of EX4 on excitability of the DR 5-HT neurons we carried out whole cell 
electrophysiology. Neurons recovered after electrical recordings were identified as 
serotoninergic by their TPH expression (Figure 5F). EX4 (1μM) applied to the superfusion buffer 
induced a rapid and reversible depolarization of the membrane potential which, in some cells, 
was sufficient to trigger action potential firing (Figure 5G).  Mean depolarization was 5.7±1.0 mV 
(p<0.002, Figure 5H). There was no change in Rinput (Figure 5I). The effect of EX4 was then tested 
after pre-incubation with Ex9-39 (1μM) to verify the specificity of its effect on 5-HT neurons. In 
this condition, EX4 did not change membrane potential (mean depolarization: -0.7±0.4mV; 
p<0.12, Figure 5H), confirming that EX4 effect is mediated by the GLP-1R. These results are in 
agreement with an excitatory effect of GLP-1R activation on DR 5-HT neurons. 
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Fibers of GLP-1-producing neurons innervate the DR 
To determine whether GLP-1-producing neurons innervate the DR, thereby providing a route via 
which the endogenous peptide could reach DR serotonin neurons, mice engineered to express 
yellow fluorescent protein (YFP) in GLP-1-producing preproglucagon (PPG) neurons were used 
(38) along with immunohistochemical detection of TPH to identify serotonin neurons. YFP-
immunoreactive innervation was assessed in coronal brain slices taken throughout the rostro-
caudal extent of the DR in YFP-PPG mice (38). YFP-immunoreactive fibers were found 
throughout the DR (Figure 6); however the dorsal and dorsolateral divisions of the DR contained 
the highest density of the YFP-immunoreactive axons. In this area many TPH-positive neurons 
were found to receive innervation from GLP-1-producing neurons (Figure 6, Figure S3: video file). 
Z-line three-dimensional reconstruction of a confocal image stack focused on a single TPH-
positive YFP-innervated neuron was used to confirm the YFP innervation, and to differentiate 
fibers terminating on the TPH-positive neuron from passing fibers. Only very sparse PPG neuron 
innervation was detected at the level of the ventral DR (Figure S4). 
Discussion 
The results presented here demonstrate that intact brain serotonin signaling is critical for 
maintenance of weight loss induced by GLP-1R activation. The time course and specific 
serotonin receptor contribution discovered here are unexpected but consistent with the 
recently emerging literature (39). Moreover, congruent results from electrophysiological, 
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immunohistochemical and neuropharmacological studies place the DR on the brain map of sites 
directly impacted by GLP-1 to regulate energy homeostasis. 
Considering the well-established role of the 5HT2C receptor in energy balance along with several 
studies indicating an opposing effect of 5HT2A and 5HT2C receptors in behavioral inhibition (40, 
41), the critical role of the 5HT2A receptor in GLP-1-induced weight loss is unexpected. However 
5HT2A and 5HT2C receptors may have similar molecular structures (42, 43). Furthermore careful 
literature investigation does suggest a perhaps overlooked role of the 2A receptor in energy 
balance regulation. Hypermethylation of 5HT2A receptor is associated with elevated baseline 
insulin levels and reduced sensitivity to the weight-loss effect of dietary interventions in human 
patients (44).  5HT2A activation in the hypothalamus attenuates hunger induced by food 
deprivation or NPY administration (45). Stimulation of 5HT2A, but not 5HT2C or 5HT1 receptors, in 
the paraventricular nucleus reduced NPY-induced hyperphagia, possibly through activation of 
CRF release (45). Finally a recent study suggests that the 2A receptor, like the 5HT2C receptor, is 
expressed on hypothalamic POMC neurons (39). In this study pharmacological activation of the 
brain 5HT2A receptors resulted in reduced food intake. Thus current results are consistent with 
several published reports that show an anorexic potential of 5HT2A receptors at the level of the 
brain. However, one study reported that peripheral injections of a 5HT2A receptor antagonist 
decrease body weight in mice (46). Thus, it seems that the anorexic effect may be driven by the 
central 5HT2A receptors, while manipulations that include peripheral receptors may have other 
effects; especially since the 5HT2A receptors are expressed on vagal afferents and other tissues, 
for examples platelets. Also 5HT2A receptor knockout mice do not show altered body weight or 
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feeding when maintained on laboratory chow, suggesting that some degree of compensation 
may be present in the knockout mice (47). Data showing that pharmacological, but not genetic, 
blockade of 5HT2C receptors attenuates LPS anorexia suggest that the manipulation of serotonin 
receptors is prone to compensatory reorganization (48). 
The 5HT2C receptor is the most extensively studied serotonin receptor in relation to food intake 
regulation (4, 11, 12). It is widely expressed in the CNS and it is also a target of a clinically 
approved anti-obesity drug. Therefore it was plausible that blockade of this receptor should 
interfere with the weight-loss and anorexic response to EX4. Our results, however, did not 
support this hypothesis. The pharmacological blockade of the 5HT2C receptor did not alter EX4-
induced reduction in food intake or fat mass. Furthermore, the body weight loss produced by 
chronic EX4 treatment seemed to be potentiated rather than attenuated by the 5HT2C receptor 
blockade. This may seem to contrast with one previous report showing that 30-minute food 
intake reduction, induced by peripheral GLP-1 injection in mice, is attenuated in 5HT2C KO mice 
(49). However, the same report states that the attenuation of anorexia was no longer significant 
at subsequent 1 and 2h measurements. Another report shows that 5HT2C KO mice display an 
attenuated anorexic response to low dose of GLP-1, but not liraglutide, at 2h (50). Thus, we may 
speculate that if 5HT2C has a contribution to anorexia resulting from GLP-1R stimulation it may 
only be relevant in a very acute setting (≤2h). On the other hand acute, 1 or 2h, anorexic 
response to liraglutide was not attenuated in mice treated with PCPA (51). These findings 
together with the current results suggest that chronic, but not acute, anorexic effect of 
liraglutide may require serotonin. Furthermore, in line with our results, the activation of 
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neurons indicated by cFos induction at 90min, after peripheral GLP-1 injection in mice, is 
actually potentiated in two hypothalamic nuclei: paraventricular and arcuate nuclei (49). It is 
also important to note that 5HT2C and 5HT2A are only two, out of at least 18 serotonin receptors, 
thus future studies should evaluate the contribution of the remaining receptors to energy 
balance regulation, especially since the mRNA of the two other receptors measured in this study 
also seems to be affected by GLP-1R activation. 
Furthermore, even though blockade of 5HT2A or 5HT2C receptors did not significantly alter 
feeding and weight loss responses acutely (<24h), this may only reflect the redundancy of the 
systems activated by GLP-1R signaling acutely. The redundancy hypothesis is also favored by 
data demonstrating 1) EX4 or GLP-1 activates DR serotonin neurons, 2) intra-DR injections of 
these agonists effectively reduce intake already at 1h, 3) they also release serotonin from 
hypothalamic synaptosomes in a matter of minutes (13). 
Dorsal raphe is a major serotonin source for the hypothalamus (15, 16). Indeed, our data 
suggest that the hypothalamus could be one of the downstream targets of GLP-1R-activated 
serotonergic neurons. These results are consistent with the critical role of the hypothalamus in 
energy balance regulation. That chronic treatment with EX4 increased serotonin turnover in the 
hypothalamus suggests that increased activity of central serotonin does not display tolerance to 
the daily GLP-1R agonist treatment. Moreover, the increased expression of 5HT2A and 5HT2C 
receptors in the hypothalamus induced by food restriction was ameliorated by either central 
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EX4 or GLP1 treatment. These results suggest that GLP-1R activation counteracts the reduced 
serotonergic activity associated with negative energy balance (52). 
Given the importance of serotonin in emotional homeostasis and the clinical application of 
serotonin-acting pharmaceuticals in the treatment of depression it was plausible that the anti-
depression impact of GLP-1 (26, 53, 54) utilizes central serotonin signaling. Surprisingly, 
blockade of either 5HT2A or 5HT2C receptors did not influence the potent anti-depression impact 
of chronic GLP-1 activation. Therefore, while serotonin signaling through the 5HT2A receptor 
proved to be critical for the energy balance effect of EX4, the impact of the drug on emotionality 
was spared by the 5HT2A receptor blockade suggesting that the interaction is critical for 
metabolic effects of GLP-1 but not necessary for emotionality regulation. Thus these findings 
disassociate the metabolic and emotionality pathways impacted by GLP-1R activation. These 
results are also consistent with the lack of a depression-like phenotype in the 5HT2A receptor 
knockout mouse (47). 
With serotonin and GLP-1 recently becoming the most relevant two brain systems for 
development of anti-obesity therapies, it is increasingly important to understand the neural 
circuitry underlying their metabolically beneficial effects. Surprisingly, little is known on how 
these two systems may interact. Current data indicate that GLP-1 avails of serotonin signaling in 
order to achieve its metabolic impact. Unexpectedly the most widely researched serotonin 
receptor, 5HT2C, was not necessary for this interaction; instead a receptor much less explored 
with respect to energy balance, 5HT2A, was shown to be critical for the hypophagic and weight 
loss impact of a clinically approved GLP-1 analogue, EX4. Our data also suggest that the effect of 
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GLP-1 on serotonin is direct since GLP-1R activation increased serotonin neuron activity, at the 
level of the DR, a key brain nucleus supplying serotonin to many forebrain areas, and caudal 
brainstem GLP-1-producing neurons innervate the DR. Our results also disassociate the brain 
metabolic and emotionality pathways impacted by GLP-1R activation. Finally few studies look at 
the long-term impact of GLP-1 analogues on the brain; this is somewhat surprising since it is the 
long-term impact that is likely the most relevant for the anti-obesity impact of these substances. 
Our data indicate that the critical neural substrates activated acutely by GLP-1 analogues may 
differ from those activated with longer-term repeated drug administration. In summary, the 
present results contribute to our understanding of neural substrates regulating food intake, 
body fat and body weight; knowledge of considerable clinical potential. Our data are preclinical, 
and thus provide an interesting avenue to explore in humans, or larger animal models where 
the data may translate more readily to humans, but currently can only be considered 
preliminary in nature. 
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Figure legends 
Fig 1. Serotonin depletion interferes with the weight-loss maintenance after central GLP-1R 
activation (A). While daily central EX4 injections in control rats led to a potent reduction of body 
weight, the weight loss impact of EX4 was markedly attenuated in rats depleted of serotonin by 
PCPA suggesting that intact serotonin synthesis is needed for a full expression of EX4-induced 
weight loss. PCPA/VEH animals did not increase in weight. n = 3–6 per each treatment group. 
Activation of central GLP-1R ameliorated changes in serotonin receptor genes in the 
hypothalamus induced by food restriction (B) and also increased serotonin turnover in the 
hypothalamus (C).  *p < 0.05, **p < 0.01, ***p < 0.005, ****p < 0.001 compared to vehicle-
treated rats. 
#
p < 0.05, 
##
p < 0.01, 
###
p < 0.005 compared to pair-fed rats. 
Fig 2. Blockade of central 5HT2C receptors does not reduce the anorexic or weight-loss effect of 
EX4. Week long daily central EX4 treatment produced a profound and sustained weight loss; 
blockade of 5HT2C receptor concurrent with the EX4 treatment did not affect the acute EX4-
induced weight loss but potentiated the EX4-induced weight loss on the remaining days of the 
treatment (A). In line with the body weight results, EX4 reduced food intake, this reduction was 
not significantly altered by the 5HT2C antagonist co-treatment (B) Similarly the reduction in the 
weight of the gonadal adipose fat pad (GWAT) induced by EX4 was spared by the concurrent 
blockade of the 5HT2C receptor (C). The impact of EX4 on depression-like behavior was 
unaltered by the chronic 5HT2C receptor blockade (D).  n = 7–16 per each treatment group. Data 
are presented as mean ± SEM.*p < 0.05, **p < 0.01, ***p < 0.005, ****p < 0.001. 
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Fig 3. Blockade of the central 5HT2A receptors attenuates the anorexic and weight-loss effect of 
EX4. Subchronic, daily central EX4 treatment produced profound and sustained weight loss; 
blockade of 5HT2A receptors concurrent with the EX4 treatment did not affect the acute EX4-
induced weight loss but abolished EX4-induced weight loss after one week (A). In line with the 
body weight results, EX4 produced a profound food intake reduction which was abolished after 
5HT2A antagonist treatment, but only after three days of co-treatment (B) Similarly the 
reduction in the weight of the gonadal adipose fat pad (GWAT) induced by EX4 was completely 
abolished by the concurrent blockade of the 5HT2A receptor (C). In contrast, the impact of EX4 
on depression-like behavior was unaltered by chronic 5HT2A receptor blockade (D). n = 6–8 per 
each treatment group. Data are presented as mean ± SEM.*p < 0.05, **p < 0.01, ***p < 0.005, 
****p < 0.001 compared to vehicle-treated rats. 
Fig 4. Blockade of the central 5HT2A receptors attenuates the anorexic and weight-loss effect of 
peripherally injected liraglutide. Daily peripheral (ip) injections of liraglutide (75 µg/kg) 
promoted weight loss; blockade of 5HT2A receptors concurrent with the liraglutide treatment 
abolished liraglutide-induced weight loss (A). In line with the body weight results, liraglutide 
reduced food intake, an effect that was attenuated by 5HT2A receptor antagonist treatment (B) 
n = 7–10 per each treatment group. Data are presented as mean ± SEM.*p < 0.05, **p < 0.01 
compared to vehicle-treated rats. 
Fig 5. Dorsal raphe GLP-1R activation is sufficient to reduce food intake and body weight and to 
increase electrical activity of DR 5-HT neurons. GLP-1 or EX4 potently reduced the amount of 
chow eaten at 1h when applied to the lateral ventricle, but only EX4 remains effective at 
reducing intake at 24h (A). n = 9–14 per each treatment group. When applied directly to the DR 
both EX4 and GLP1 reduce food intake at 1h and 24h (B). The weight loss at 24h did not reach 
significance for either of the two compounds (C). n = 7–10 per each treatment group. Data are 
expressed as mean ± SEM. Photomicrograph of a 40μm coronal section of rat brain illustrating 
the injection site and schematic representation of the DR according to the rat brain atlas (D-E).  
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The red circle illustrates the detected diffusion of ink. Immunohistochemical identification of 
TPH expression (red) in a biocytin-filled (green) DR 5-HT neuron (arrowhead) (F). Scale bar: 20 
µm. Voltage trace obtained from whole-cell recordings from DR 5-HT neurons showing the 
response of a DR 5-HT neuron to EX4 (1 µM, arrowhead) (G). Bar graphs summarizing EX4 effect 
on Vm (H) and Rinput (I) on DR 5-HT neurons in baseline condition or after pre-incubation with 
Ex9-39 1 µM (n=6). DRD, DRL, and DRL: dorsal, lateral and ventral subdivisions of the dorsal 
raphe, respectively. Data are presented as mean ± SEM; *p < 0.05, **p < 0.01, ***p < 0.005. 
Fig 6. Immunohistochemical labeling for YFP in YFP–PPG neurons (green) and 5-HT in serotonin 
neurons (red) in coronal sections through the DR nucleus of YFP–PPG mice. Low magnification 
micrographs showing the rostro-caudal extent of the DR examined (A-C). Groups of red 5-HT-
immmunoreactive cell bodies are shown at higher magnification in D-I. Higher magnification of 
the dorsal subregion of the DR is displayed in D-E, and of the lateral subregion in G-I. For each of 
these subregions examples of individual TPH-positive neurons receiving YFP-labeled innervation 
from GLP-1-producing neurons are shown in the bottom left corner of each panel. Innervation 
of chosen individual neurons was confirmed by creating a three dimensional reconstruction of 
Z-stack images (Fig S4). High levels of immunoreactive YFP fibers are found in both the 
dorsolateral and dorsal section of the DR but not in the ventral section (Fig S4).   
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Fig 1. Serotonin depletion interferes with the weight-loss maintenance after central GLP-1R activation (A). 
While daily central EX4 injections in control rats led to a potent reduction of body weight, the weight loss 
impact of EX4 was markedly attenuated in rats depleted of serotonin by PCPA suggesting that intact 
serotonin synthesis is needed for a full expression of EX4-induced weight loss. PCPA/VEH animals did not 
increase in weight. n = 3–6 per each treatment group. Activation of central GLP-1R ameliorates changes in 
serotonin receptor genes in the hypothalamus induced by food restriction (B) and also increases serotonin 
turnover in the hypothalamus (C).  *p < 0.05, **p < 0.01, ***p < 0.005, ****p < 0.001 compared to 
vehicle-treated rats. #p < 0.05, ##p < 0.01, ###p < 0.005 compared to pair-  fed rats.
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Fig 2. Blockade of central 5HT2C receptors does not reduce the anorexic or weight-loss effect of EX4. Week 
long daily central EX4 treatment produced a profound and sustained weight loss; blockade of 5HT2C 
receptor concurrent with the EX4 treatment did not affect the acute EX4-induced weight loss but potentiated 
the EX4-induced weight loss on the remaining days of the treatment (A). In line with the body weight 
results, EX4 produced a profound food intake reduction which was not significantly altered by the 5HT2C 
antagonist co-treatment (B) Similarly the reduction in the weight of the gonadal adipose fat pad (GWAT) 
induced by EX4 was spared by the concurrent blockade of the 5HT2C receptor (C). The impact of EX4 on 
depression-like behavior was unaltered by the chronic 5HT2C receptor blockade (D).  n = 7–16 per each 
treatment group. Data are presented as mean ± SEM.*p < 0.05, **p < 0.01, ***p < 0.005, ****p < 
0.001. 
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Fig 3. Blockade of the central 5HT2A receptors attenuates the anorexic and weight-loss effect of EX4. 
Subchronic, daily central EX4 treatment produced profound and sustained weight loss; blockade of 5HT2A 
receptors concurrent with the EX4 treatment did not affect the acute EX4-induced weight loss but abolished 
EX4 weight loss after one week (A) In line with the body weight results, EX4 produced a profound food 
intake reduction which was abolished after 5HT2A antagonist treatment but only after three days of co-
treatment (B) Similarly the reduction in the weight of the gonadal adipose fat pad (GWAT) induced by EX4 
was completely abolished by the concurrent blockade of the 5HT2A receptor (C). In contrast, the impact of 
EX4 on depression-like behavior was unaltered by chronic 5HT2A receptor blockade (D).  n = 6–8 per each 
treatment group. Data are presented as mean ± SEM.*p < 0.05, **p < 0.01, ***p < 0.005, ****p < 0.001 
compared to vehicle-treated rats.  
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Fig 4. Blockade of the central 5HT2A receptors attenuates the anorexic and weight-loss effect of peripherally 
injected liraglutide. Daily peripheral injections of liraglutide (75 µg/kg) promoted weight loss; blockade of 
5HT2A receptors concurrent with the liraglutide treatment abolished liraglutide-induced weight loss (A) In 
line with the body weight results, liraglutide reduced food intake, an effect that was attenuated by 5HT2A 
receptor antagonist treatment (B) n = 7–10 per each treatment group. Data are presented as mean ± 
SEM.*p < 0.05, **p < 0.01 compared to vehicle-treated rats.  
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Fig 5. Dorsal raphe GLP-1R activation was sufficient to reduce food intake and body weight and to increase 
electrical activity of DR 5-HT neurons. GLP-1 or EX4 potently reduce the amount of chow eaten at 1h when 
applied to the lateral ventricle, but only EX4 remains effective at reducing intake at 24h (A). n = 9–14 per 
each treatment group. When applied directly to the DR both EX4 and GLP1 reduce food intake at 1h and 24h 
(B). The weight loss at 24h did not reach significance for either of the two compounds (C). n = 7–10 per 
each treatment group. Data are expressed as mean ± SEM. Photomicrograph of a 40µm coronal section of 
rat brain illustrating the injection site and schematic representation of the dorsal raphe according to the rat 
brain atlas (D-E).  The red circle illustrates the detected diffusion of ink. Immunohistochemical identification 
of TPH expression (red) in a biocytin-filled (green) DR 5-HT neuron (arrowhead) (F). Scale bar: 20 µm. 
Voltage trace obtained from whole-cell recordings from DR 5-HT neurons showing the response of a DR 5-HT 
neuron to EX4 (1 µM, arrowhead) (G). Bar graphs summarizing EX4 effect on Vm (H) and Rinput (I) on DR 
5-HT neurons in baseline condition or after pre-incubation with Ex9-39 1 µM (n=6). DRD, DRL, and DRL: 
dorsal, lateral and ventral subdivisions of the dorsal raphe, respectively. Data are presented as mean ± 
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SEM; *p < 0.05, **p < 0.01, ***p < 0.005. 
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Fig 6. Immunohistochemical labeling for YFP in YFP–PPG neurons (green) and 5-HT in serotonin neurons 
(red) in coronal sections through the DR nucleus of YFP–PPG mice. Low magnification micrographs showing 
the rostro-caudal extent of the DR examined (A-C). Groups of red 5-HT-immmunoreactive cell bodies are 
shown at higher magnification in D-I. Higher magnification of the dorsal subregion of the DR is displayed in 
D-E, and of the lateral subregion in G-I. For each of these subregions examples of individual TPH-positive 
neurons receiving YFP-labeled innervation from GLP-1-producing neurons are shown in the bottom left 
corner of each panel. Innervation of chosen individual neurons was confirmed by creating a three 
dimensional reconstruction of Z-stack images (Fig S4). High levels of immunoreactive YFP fibers are found in 
both the dorsolateral and dorsal section of the DR but not in the ventral section (Fig S5). 
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Glucagon-like peptide-1 acts in the dorsal raphe and modulates central serotonin to reduce appetite 
and body weight. 
Anderberg et al.  
SI Appendix 
Table 1: TaqMan probe and primer sets for target genes examined in the hypothalamus. 
Gene 
symbol 
Gene name Assay ID 
Htr1a 5-hydroxytryptamine (serotonin) receptor 1A Rn00561409_s1 
Htr2a 5-hydroxytryptamine (serotonin) receptor 2A Rn00568473_m1 
Htr2c 5-hydroxytryptamine (serotonin) receptor 2C Rn00562748_m1 
Htr3a 5-hydroxytryptamine (serotonin) receptor 3A Rn00667026_m1 
Table 2: Antibodies, manufacturers, and dilutions. Grey background indicates antibodies used in the YFP-
mice. In yellow antibodies used to confirm serotonergic identity of neurons after whole-cell 
electrophysiology in rats.  
Antibody name Manufacturer Lot # Dilution 
YFP Abcam, Cambridge, UK ab13970 1/600 
TPH Sigma-Aldrich, USA T0678 1/500 
Alexa Fluor 488® Abcam ab150169 1/400 
Alexa Fluor 568® Abcam ab175700 1/800 
Cy3-donkey anti-mouse Jackson Immuno 
Research 
715-165-150 1/200 
TPH Sigma-Aldrich, USA T0678 1/500 
Alexa Fluor 488-
streptavidin 
Invitrogen S11223 1/200 
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Fig S1. The food restricted rats pair-fed  to the amount eaten by the EX4-tretaed rats did not 
receive central injections. In order to confirm that the difference in serotonin receptor expression 
persists if the cannulation/injection state of the rats is matched an extra control group of rats not 
injected or cannulated was tested along with the rats whose intake was restricted to the amount 
eaten by EX4-injected rats. The new data show that the increased expression of 5ht2a and 5ht2c 
receptors can still be found when both the control group and the food-restricted group do not 
receive injections or cannulation surgery. The 50% increase in mRNA expression of the 2A and 2C 
receptors is similar to that presented in Figure 1B. This control experiment suggests that the 
change in serotonin receptor expression is not brain injection-dependent. # p=0.06, * p<0.05 
Fig S2. Dorsal raphe GLP-2 injections did not change food intake or body weight. Neither 1h nor 
24h food intake was significantly altered by DR-directed GLP-2 microinjection (A). Body weight 
was also not changed by the treatment (B). GLP-2 was injected at a dose of 2µg/0.2µL.  
Fig S3 (Video file). Z-line three dimensional reconstruction of a confocal image stack shown an 
example of a YFP-innervated neuron. Displayed here Z-stack was collected from 6 layers taken at 
1uM apart. The movie shows a three dimensional spin around the vertical axis.  
Fig S4. Immunohistochemical labeling for YFP in YFP–PPG neurons (green) and 5-HT in serotonin 
neurons (red) in coronal sections through the DR nucleus of YFP–PPG mice. Low magnification 
micrographs showing the rostro-caudal extent of the DR examined (A-C) with a rat atlas based 
overlay indicating subnuclei of the DR. Groups of red 5-HT-immmunoreactive cell bodies are 
shown at higher magnification in D-F. Little to no immunoreactive YFP fibers are found in the 
ventral sections of the DR (G-I), however the few individual neurons determined to receive YFP-
labeled innervation are displayed in J-M.   
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